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The range of doses achieved for D2cc Rectum was 52.46 Gy to 
138.27 Gy. 85% of cases achieved D10 Urethra of less than 
217.5Gy, whilst 100% achieved doses of less than 240 Gy. The 
range of doses for D30 Urethra was 172.08 Gy to 222.35 Gy. 
64% of cases received doses greater than 188.5Gy but only 
7.4% of cases received doses greater than 208 Gy. Only 1 
patient required re-catheterisation post procedure. 
Conclusions: The median dosimetric parameters ascribed to 
a 145Gy prescription dose were achieved for all GEC-ESTRO 
described organs at risk, except for the secondary OAR 
parameter of D30 Urethra, using a prescription dose of 160Gy. 
The low rectal doses are noteworthy as is the low rate of re-
catheterisation. This indicates that 160Gy can be safely 
delivered which may in turn improve outcomes. 
   
PO-1050   
Comparison of two different types of stranded 125-I seeds 
for permanent prostate brachytherapy 
B. Polat1, S. Glatz2, K. Baier1, M. Noe3, M. Flentje1 
1University Hospital Würzburg, Department of Radiation 
Oncology, Würzburg, Germany  
2University Hospital Zürich, Department of Radiation 
Oncology, Zürich, Switzerland  
3Missionsärztliches Krankenhaus, Department of Urology, 
Würzburg, Germany  
 
Purpose/Objective: To evaluate two different types of 
stranded seeds in permanent prostate brachytherapy. In the 
first group we used strands with a fixed sequence of seeds 
and spacers, in the second group we could implant strands 
with a variable sequence of seeds and spacers. 
Materials and Methods: From 2007 to 2014 we treated a 
total of 110 low-risk prostate cancer patients with either the 
fixed (IsoCord®, Eckert & Ziegler Bebig, n=74) or the variable 
spacing (Quicklink®, C.R. Bard, n=36) system. Median patient 
age was 65.5 years. All patients were treated by the same 
team of radiation oncologist, urologist and physicist. 
Treatment planning parameters were compared at seed 
implantation and at post-planning 4 weeks later. Toxicities 
and quality of life were evaluated according to CTCAE v4 and 
the EORTC QLQ-C30 and PR-25 questionnaires. To evaluate 
obstructive problems we used the IPSS scoring system. 
Results: Mean prostate volumes were 30.4+11ccm and 
36.9+11ccm (p=0,004). A mean of 52 vs 59 Seeds per patient 
were implanted (p<0,001). At implantation values for D90 
(191.9 vs. 179.9Gy; p<0,001), V100 (99.1 vs. 97.6%; p<0,001), 
V150 (78.5 vs. 70.5%; p<0,001) and V200 (45.1 vs. 37.9%; 
p<0,001) were significantly different. Also D1 for urethra was 
less for the group with variable spacing (225.9 vs. 206.8Gy; 
p<0,001). We observed significant differences at post-
planning in the following DVH parameters: D90 (165.7 vs. 
171.9Gy; p=0,008) and V100 (94.6 vs. 96.0; p<0.001). The 
reduction in D90 values were significantly greater for the 
fixed system (13.7% vs. 4.6%; p<0.001). Homogeneity index 
was significantly different at implantation (20.8 vs. 27.2%) 
but not at post planning (24.8 vs. 25.0%). There were no 
significant changes in rectal V100 and prostate V150 and 
V200. Evaluation of toxicities, IPSS scores and comparison of 
quality of life parameters is still ongoing and will be 
presented at the conference. 
Conclusions: Using the stranded seed system with variable 
spacing we could achieve a reduced dose to the urethra at 
implantation and observed more stable values for prostate 
D90 at post-planning dosimetry.  
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Purpose/Objective: Development of new technologies and 
the applicator MRI studies for the intracavitary radiation 
therapy for cancer of the anal canal, with the aim 
Enhancements treatment results and brachytherapy planning 
and optimization The prognostic relevance of tumor human 
papilloma virus (HPV) status in patients with anal squamous 
cell carcinoma. 
Materials and Methods: in 2012-2014 40 invasive anal 
channel cancer T1-4 N0-1 M0 patients were treated with 
combined chemoradiotherapy. First the patients received 
chemoradiotherapy using cisplatin and capecitabin. EBT was 
performed for minor pelvis and local lymph nodes using a 3D 
technique, since 2010 using IMRT and RapidArc. Total dose 
was 45 Gr. HPV status was revealed using an anal channel 
smear and PCR. At the second phase of radiotherapy - 
brachytherapy applicator used by us made, 25mm diameter, 
with 6 peripheral channels and one central, for the 
MicroSelectron was performed: All training conducted 
dosimetry using MRI scans. Optimal single dose per fraction is 
calculated by a special formula.  
The irradiation was performed three a week, 3 Gy per 
fraction. 5-6 fractions were performed. Total radiation 
dose=18-21Gy. 
Comparison and optimization treatment plans was performed 
with the following parameters: Coverage index, External 
volume index, Relative Dose Homogeneity index, Overdose 
volume index. 
Results: 36 patients out of 40 achieved complete regression 
of the tumor. Annual relapse-free survival rate was 98 
percent of 40 patients, 36 had positive HPV status. Full 
regress of the primary tumor was obtained in 36 (100%) 
patients. Of HPV negative status patients, full response was 
obtained only in 1 patient. 
Conclusions: Applying the new applicator may achieve 
optimal dose distribution and to achieve a greater 
percentage of complete regression. In anal channel patients 
receiving combined chemoradiotherapy, an HPV positive 
status is a favorable prognostic factor of a tumor´s 
radiosensitivity. 
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